Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SPD602 · 1 trial · 2 indications
LIC was determined by R2 Magnetic Resonance Imaging (MRI).
| Arm | Type | Description |
|---|---|---|
| SPD602 (16mg) | EXPERIMENTAL | - |
| SPD602 (32mg) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SPD602 (FBS0701, SSP-004184) | DRUG | Oral FBS0701 taken one time daily for up to 96 weeks. |
Inclusion Criteria: * Transfusional iron overload due to: hereditary anemias such as sickle cell disease, β-thalassemia and Diamond-Blackfan anemia; acquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure. Patients must also be transfusion-dependent and require chro...
SPD602 is an investigational small molecule being developed for the treatment of transfusional iron overload, a condition that can occur in patients who receive regular blood transfusions, such as those with beta-thalassemia. It is designed to be taken orally as an iron chelator.
SPD602 is an oral iron chelator. It works by binding to excess iron in the body and promoting its excretion, thereby reducing iron accumulation in patients with transfusional iron overload. This mechanism helps manage the toxic effects of iron overload.
SPD602 is being developed by Takeda Pharmaceutical Company Limited, a global biopharmaceutical company. Takeda's stock is listed on the New York Stock Exchange under the ticker symbol TAK.
SPD602 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed to evaluate its safety and pharmacodynamic effects in patients with iron overload.
SPD602 has been studied in one completed Phase 2 clinical trial, identified as NCT01186419. This trial was a controlled, randomized study that enrolled 51 participants with transfusional iron overload or beta-thalassemia. The study was conducted in the United States, Italy, Thailand, Turkey, and the United Kingdom.
SPD602 is an oral iron chelator, a type of medication that binds to excess iron in the body to help remove it. It is being developed as a treatment for transfusional iron overload, and its mechanism of action is similar to other drugs in this class.